Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma Inc (NQ: SILO )

1.770 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Silo Pharma Inc

< Previous 1 2 3 4 Next >
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Participation at Upcoming Psychedelic Drug Development Conference
Via Investor Brand Network
Silo Pharma to Present at Psychedelic Drug Development Conference
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Development of Treatment for Anxiety-Related Disorders
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
ENGLEWOOD CLIFFS, NJ – April 19, 2023 – Silo Pharma, Inc. (NASDAQ:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic... 
Via FinancialNewsMedia
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
Data to Support Alzheimer’s Study 
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Positioned as Frontrunner in Psychedelic Drugs Market
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Positive Results from IND-Enabling Toxicology Study of SP-26
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression
Via Investor Brand Network
Exposures COVID-19
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands Intellectual Property, Technology Rights for Treating Rare Stress-Related Medical Conditions
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma Inc. (NASDAQ: SILO) Granted US Patent For SPC-15 to Prevent and Treat Stress-Induced Disorders
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Alzheimer’s
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands IP Portfolio with New USPTO Patent
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma Announces Expansion of Intellectual Property Portfolio
Silo Receives Issuance of U.S. Patent Covering SPC-15 Method for Treatment and Prevention of Stress-Induced Affective Disorders 
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Board Authorizes Stock Repurchase Program
Via Investor Brand Network
Silo Pharma Announces Stock Repurchase Program
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical Trial
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Eying Broad Market Opportunities for Its Liposomal Joint Homing Peptide
Via Investor Brand Network
Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis
Via Investor Brand Network
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Clinical Study Examining Psilocybin’s Effect on Inflammation
Via Investor Brand Network
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Results from SPU- 21 Arthritis Study
Via Investor Brand Network
Silo Pharma (NASDAQ: SILO) Reports Positive Results from Dose Optimization Study for SPU-21 and Treatment of Arthritis
Silo Pharma, Inc. (NASDAQ: SILO) operates as a development-stage biopharmaceutical company, which is focused on combining traditional therapies with psychedelics 
Via Spotlight Growth
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END 
Via FinancialNewsMedia
Silo Pharma Announces Positive Study Results of SPU
21 for Arthritis – SPU-21 effective in controlling arthritis progression SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide Englewood Cliffs, – December... 
Via FinancialNewsMedia
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.